查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002823

細胞免疫療法市場：按類型、技術、適應症和設施分類－2026-2032年全球預測

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞免疫療法市場價值將達到 246.2 億美元，到 2026 年將成長至 261.9 億美元，到 2032 年將達到 388.1 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年 2025 246.2億美元
預計年份：2026年 261.9億美元
預測年份 2032 388.1億美元
複合年成長率 (%) 6.71%

引言概述了塑造現代細胞免疫療法的科學創新、臨床需求和操作複雜性的融合。

細胞免疫療法領域正步入科學、臨床實踐和商業策略融合的新階段，這為整個價值鏈上的相關人員帶來了獨特的機會和營運挑戰。基因修飾細胞平台的最新進展，以及生產和監管流程的不斷改進，正在擴大可用的治療方法範圍。同時，人們對安全性、療效持久性和成本效益的日益成長的期望，正在重塑研發人員、臨床試驗中心和合作方對投資和規模化生產的優先排序。

分析技術多元化、業務規模和夥伴關係模式如何重塑細胞療法的轉化路徑和商業化準備。

在技​​術突破和相關人員期望轉變的雙重推動下，變革性的變化正從多個角度重新定義細胞免疫療法。治療方法正從第一代過繼性細胞療法走向多元化，如今已涵蓋更複雜的工程技術、改進的安全開關以及結合細胞療法和靶向生技藥品的混合平台。這種多元化促使人們重新評估研發路徑，因為申辦方力求在實現差異化療效潛力的同時，兼顧日益複雜的生產製造和法律規範。

對不斷上漲的關稅趨勢將如何影響整個細胞治療價值鏈的供應鏈、生產連續性和專案進度安排進行策略性評估。

新關稅和貿易措施的訂定給細胞免疫療法計畫帶來了巨大的營運壓力。當關鍵投入品需要跨境採購或專用設備依賴少數供應商時，這種影響尤其顯著。試劑、一次性耗材和精密儀器的供應商導致成本增加，會立即造成採購壓力，迫使各機構重新評估其籌資策略和庫存政策。實際上，這通常會導致前置作業時間延長、營運資金需求增加，以及需要檢驗替代供應商以維持臨床和生產活動的正常進行。

基於對治療方法、相關技術、適應症和設施能力進行觀點分析的可操作策略設計。

細分分析在將研發策略與患者群體、生產路徑和設施能力相匹配時，能夠提供至關重要的清晰資訊。根據類型，該領域包括 CAR-T 細胞療法、樹突細胞療法、NK 細胞療法、T 細胞受體療法和腫瘤浸潤淋巴細胞療法，每種療法都有不同的研發進度、安全性特徵和生產需求。例如，基因修飾的 CAR-T 構建體需要複雜的病毒載體生產和嚴格的療效檢測，而 NK 細胞療法可能更依賴增殖通訊協定和現成的物流。

區域間監管合規性、商業性准入和基礎設施規模的比較決定了全球市場的採用路徑。

區域趨勢對細胞免疫療法的研發策略、監管路徑和市場准入有著根本性的影響。在美洲，完善的基礎設施、支付方合作模式和臨床試驗網路支持快速招募患者並不斷累積證據；然而，商業化需要與報銷相關人員密切合作，以證明其價值和長期療效。儘管區域法規結構正透過快速核准途徑不斷擴大對先進治療方法的回應範圍，但製造商仍必須應對複雜的生產合規要求和核准後證據要求。

公司層面的策略分析表明，整合的臨床研發管線、生產能力和智慧財產權策略如何創造競爭優勢和合作優勢。

細胞免疫療法領域的競爭格局由臨床研發管線、製造地、智慧財產權策略和策略聯盟等因素共同塑造。主要企業強調採用整合式方法，將強大的臨床開發能力與可擴展的生產能力和全面的品管系統結合。隨著各企業努力降低產品變異性並縮短批次放行時間，對封閉式生產系統、自動化和供應鏈可追溯性的投資正成為通用的優先事項。

加強製造業韌性的經營團隊實用建議：使證據生成與獲取需求一致，並確保建立策略夥伴關係以實現永續商業化

行業領導者必須採取果斷行動，將科學進步轉化為永續的臨床和商業性成果。首先，他們應優先投資於模組化和可擴展的生產製造，以支援基於適應症的不同平台的一致性，同時融入自動化和品質源自於設計 (QbD) 原則，以減少批次間的差異。這項投資應與供應商多元化和區域籌資策略相結合，以減輕貿易和關稅帶來的衝擊。其次，他們應建立超越單純貿易關係的夥伴關係理念，與合約研究組織、醫院和研究機構建立合作開發框架，並在產能、資料共用和共同監管目標方面協調各方獎勵。

為了確保獲得可操作的見解，我們採取了透明、多方面的研究途徑，將與主要相關人員的對話、二手證據的整合和專家檢驗相結合。

本分析採用嚴謹的質性和量性相結合的調查方法，以確保研究結果的可靠性和效度。主要研究工作包括對整個生態系統中的相關人員進行結構化檢驗和深入討論，這些利害關係人包括臨床研究人員、生產管理人員、監管專家和商業負責人。透過這些對話，我們了解了實際營運情況、策略重點和基於經驗的洞見，這些都構成了提出切實可行建議的基礎。

簡明扼要地闡述了技術創新、營運準備和策略遠見對於實現細胞療法的潛力至關重要的協調一致。

總之，細胞免疫療法正處於一個轉折點，需要科學進步與營運準備的和諧融合才能充分發揮其治療潛力。技術多樣化拓展了臨床應用的可能性，但同時也提高了對生產精度、供應鏈穩健性和能夠支持規模化生產和確保患者療效一致性的戰略夥伴關係模式的要求。政策和貿易趨勢也帶來了進一步的限制，因此，積極主動的籌資策略和基於情境的規劃至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 細胞免疫療法市場：按類型分類

  • CAR-T細胞療法
  • 樹突細胞療法
  • NK細胞療法
  • T細胞受體療法
  • 腫瘤浸潤淋巴細胞療法

第9章：細胞免疫療法市場：依技術類型分類

  • 細胞激素和免疫調節劑
  • 單株抗體

第10章 細胞免疫療法市場：依適應症分類

  • B細胞惡性腫瘤
  • 肝癌
  • 攝護腺癌
  • 腎臟細胞癌

第11章 機構細胞免疫療法市場

  • 學術機構
  • 生物技術和製藥公司
  • 承包組織
  • 醫院
  • 研究機構

第12章 細胞免疫療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 細胞免疫療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 細胞免疫療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國細胞免疫療法市場

第16章 中國細胞免疫療法市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bellicum Phamaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics BV
  • Immatics NV
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market was valued at USD 24.62 billion in 2025 and is projected to grow to USD 26.19 billion in 2026, with a CAGR of 6.71%, reaching USD 38.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.62 billion
Estimated Year [2026] USD 26.19 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.71%

A focused introduction that frames the convergence of scientific innovation clinical demands and operational complexities shaping modern cellular immunotherapy

The cellular immunotherapy landscape has entered a phase where science, clinical practice, and commercial strategy converge to create distinct opportunities and operational challenges for stakeholders across the value chain. Recent advances in engineered cell platforms, coupled with iterative improvements in manufacturing and regulatory pathways, have expanded the scope of adoptable therapeutic approaches. At the same time, rising expectations around safety, durability of response, and cost-effectiveness are reshaping how developers, clinical centers, and contract partners prioritize investment and scale-up.

As a result, decision-makers must reconcile clinical promise with logistical realities. Translational progress has accelerated candidate pipelines from early discovery into pivotal studies, but this trajectory demands robust supply chains, quality management systems, and strategic partnerships to ensure reproducible outcomes. Equally important, payers and providers are scrutinizing evidence generation strategies and real-world performance to support reimbursement and access. In this context, a clear-eyed introduction clarifies the interplay between technological evolution and practical implementation, setting the stage for deeper analysis of market shifts, policy headwinds, and organizational imperatives that follow.

An analysis of how technological diversification operational scale and partnership models are reshaping translational pathways and commercial readiness in cell therapy

Transformative shifts are redefining cellular immunotherapy across multiple dimensions, and these changes are driven by both technological breakthroughs and evolving stakeholder expectations. Therapeutic modalities are diversifying beyond first-generation adoptive cell therapies to include more refined engineering approaches, improved safety switches, and hybrid platforms that combine cellular agents with targeted biologics. This diversification is prompting re-evaluation of development paths, as sponsors balance the potential for differentiated efficacy against increased complexity in manufacturing and regulatory oversight.

Concurrently, manufacturing is transitioning from bespoke, center-based production toward more standardized, modular, and scalable processes. Advances in automation, closed-system workflows, and quality-by-design approaches are enabling higher throughput while aiming to reduce batch variability. These operational improvements are complemented by a growing emphasis on decentralized clinical networks and strategic alliances between biotechnology companies, clinical institutions, and specialized contract organizations. Accordingly, partnerships are evolving from transactional vendor relationships into integrated collaborations focused on co-development, shared risk, and capacity alignment. Taken together, these shifts are accelerating clinical translation while simultaneously elevating the importance of rigorous process control and strategic alignment among stakeholders.

A strategic assessment of how elevated tariff dynamics influence supply chains manufacturing continuity and program timelines across the cell therapy value chain

The introduction of new tariffs and trade measures presents a material operational stressor for cellular immunotherapy programs, particularly where key inputs cross borders or where specialized equipment originates from a narrow set of suppliers. Tariff-driven cost increases on reagents, single-use consumables, and precision instruments can create immediate procurement pressure, prompting organizations to reassess sourcing strategies and inventory policies. In practice, this often translates into longer lead times, elevated working capital requirements, and the need to validate alternative suppliers to maintain uninterrupted clinical and manufacturing activities.

Beyond direct cost impacts, tariffs can amplify supply chain fragility by reducing the resilience of global component flows and incentivizing nearshoring or regional reshoring initiatives. Companies that previously relied on international vendor networks may encounter renegotiation of supplier contracts or delays in equipment deployment, which in turn can affect study enrollment timelines and manufacturing scale-up plans. To mitigate these risks, many organizations are evaluating localized supplier development, multi-sourcing strategies, and strategic inventory buffers, while also escalating dialogue with regulatory bodies about acceptable equivalence and qualification pathways for alternate materials.

Importantly, the cumulative effect of tariff pressures is often felt unevenly across the value chain. Smaller biotech developers and academic centers with constrained procurement leverage may experience disproportionate operational strain, whereas larger organizations with diversified supply bases and in-house manufacturing capabilities might better absorb short-term shocks. However, prolonged tariff environments have the potential to redirect investment priorities, accelerate consolidation of supply relationships, and incentivize the development of domestic manufacturing capacity where regulatory and economic conditions permit. Stakeholders should therefore integrate tariff scenario planning into clinical development and commercialization roadmaps to maintain program continuity and strategic flexibility.

Insightful segmentation-driven perspectives that align therapy modalities adjunct technologies indications and institutional capabilities for actionable strategy design

Segmentation analysis offers critical clarity when aligning development strategies to patient populations, manufacturing pathways, and institutional capabilities. Based on Type, the landscape encompasses CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, T-Cell Receptor Therapy, and Tumor-Infiltrating Lymphocytes Therapy, each presenting distinct development timelines, safety profiles, and manufacturing needs. For example, engineered CAR T constructs demand sophisticated viral vector production and stringent potency assays, whereas NK cell approaches may emphasize expansion protocols and off-the-shelf logistics.

Based on Technology Type, the field differentiates between Cytokines & Immunomodulators and Monoclonal Antibodies, which interact with cellular therapies in combinatorial regimens and supportive care strategies. These adjunct technologies shape clinical trial design, biomarker strategies, and dosing paradigms, influencing both efficacy benchmarks and regulatory expectations. Based on Indication, the therapeutic focus spans B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma, each indication requiring tailored clinical endpoints, patient selection criteria, and evidence-generation approaches to demonstrate meaningful benefit.

Based on Institution Category, the ecosystem includes Academic Institutes, Biotech & Pharmaceutical Companies, Contract Organizations, Hospitals, and Research Institutes, with each actor contributing unique capabilities. Academic institutes often lead early translational research and investigator-initiated trials; biotech and pharmaceutical companies drive clinical development and commercialization strategy; contract organizations deliver scale-up and manufacturing services; hospitals provide clinical trial sites and real-world data capture; and research institutes contribute foundational science and biomarker discovery. Recognizing how these segments intersect helps stakeholders prioritize investments, select partners, and design clinical programs that reflect therapeutic modality, technological adjuncts, target indications, and institutional strengths.

Comparative regional perspectives on regulatory readiness commercial access and infrastructure scale that determine adoption pathways across global markets

Regional dynamics fundamentally affect development strategies, regulatory pathways, and commercial access for cellular immunotherapies. In the Americas, infrastructure depth, payer engagement models, and clinical trial networks support rapid patient accrual and iterative evidence generation, while commercialization requires close coordination with reimbursement stakeholders to demonstrate value and long-term outcomes. Regulatory frameworks in this region increasingly accommodate advanced therapies through expedited pathways, yet manufacturers must still navigate complex manufacturing compliance and post-approval evidence commitments.

Across Europe, Middle East & Africa, regulatory plurality and diverse healthcare financing structures create both opportunities and challenges. Certain European jurisdictions offer innovative reimbursement mechanisms for high-cost therapies, but broader market access often requires adaptive evidence strategies and region-specific health economic modeling. In some Middle Eastern and African markets, the emphasis rests on capacity building, infrastructure development, and clinician training to support safe and effective administration of cellular therapies.

The Asia-Pacific region is characterized by heterogeneity in regulatory maturity, manufacturing capacity, and clinical adoption rates. Some markets in the region are rapidly expanding local production capabilities and investing in clinical trial infrastructure, while others focus on strategic collaborations with global sponsors to access novel therapies. Across all regions, cross-border collaborations, regulatory harmonization efforts, and investments in workforce and facility readiness will be decisive factors shaping the pace at which these therapies move from clinical proof-of-concept to routine clinical practice.

Strategic company-level observations showing how integrated clinical pipelines manufacturing capabilities and IP strategies drive competitive advantage and partnership leverage

Competitive dynamics in cellular immunotherapy are shaped by a combination of clinical pipelines, manufacturing footprints, intellectual property strategies, and strategic alliances. Leading organizations emphasize an integrated approach that aligns robust clinical development with scalable manufacturing capabilities and comprehensive quality systems. Investment in closed-system manufacturing, automation, and supply chain traceability emerges as a common priority, as firms seek to reduce variability and accelerate batch release timelines.

Strategic collaborations between developers and specialized contract organizations are becoming more sophisticated, with partners co-designing manufacturing processes, sharing validation data, and coordinating regulatory submissions. Companies that prioritize platform extensibility, regulatory engagement, and real-world evidence generation typically preserve optionality across indications and combinations. Intellectual property stewardship also plays a critical role; organizations with clear freedom-to-operate and strong patent portfolios tend to command greater negotiating leverage when forming licensing deals or co-development partnerships.

Finally, corporate strategies increasingly recognize the importance of integrated commercial planning. Cross-functional alignment between clinical development, regulatory affairs, manufacturing, and market access teams underpins successful launches. Firms that proactively model provider workflows, reimbursement pathways, and long-term safety monitoring requirements position themselves to convert clinical success into sustainable clinical adoption and payer acceptance.

Actionable recommendations for executives to strengthen manufacturing resilience align evidence generation with access needs and secure strategic partnerships for durable commercialization

Industry leaders must act decisively to convert scientific progress into durable clinical and commercial outcomes. First, prioritize modular and scalable manufacturing investments that support platform consistency across indications, while incorporating automation and quality-by-design principles to reduce batch variability. This investment should be paired with supplier diversification and regional sourcing strategies to mitigate trade and tariff disruptions. Second, adopt a partnerships mindset that moves beyond transactional relationships to form co-development arrangements with contract organizations, hospitals, and research institutes, aligning incentives around capacity, data sharing, and mutual regulatory goals.

Third, integrate evidence generation across clinical and real-world settings by designing trials with pragmatic endpoints and post-approval registries that address payer and provider requirements. Early engagement with reimbursement authorities and HTA bodies will streamline pathways to access and inform commercial pricing strategies. Fourth, strengthen talent pipelines and operational governance by investing in cross-functional teams that bridge clinical, manufacturing, quality, and commercial expertise, ensuring rapid decision-making during scale-up and launch phases.

Finally, build strategic resilience through scenario planning that encompasses trade policy changes, supply chain disruptions, and shifts in reimbursement. By simulating alternative procurement and clinical deployment pathways, leaders can reduce time-to-resolution for operational contingencies and preserve momentum across development milestones. Collectively, these actions help organizations translate innovation into reliable patient access and sustainable business models.

A transparent and multi-method research approach combining primary stakeholder engagement secondary evidence synthesis and expert validation to ensure actionable insights

The research methodology driving this analysis combined rigorous qualitative and quantitative approaches to ensure robust and validated insights. Primary research consisted of structured interviews and in-depth discussions with stakeholders across the ecosystem, including clinical investigators, manufacturing leaders, regulatory experts, and commercial strategists. These engagements captured operational realities, strategic priorities, and experiential learnings that underpin practical recommendations.

Secondary research included a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trends, clinical endpoints, and regulatory milestones. Data triangulation was employed to reconcile divergent perspectives and to validate assertions across sources. An iterative synthesis process integrated thematic analysis with scenario planning to surface material risks and strategic opportunities.

Quality assurance measures involved expert panel reviews and internal validation checks to confirm factual accuracy and relevance. Where appropriate, methodological caveats and confidence qualifiers were noted to indicate areas where evidence remains emergent or where industry practice is still evolving. This combined approach ensures that the conclusions and recommendations are grounded in contemporary practice and reflect the operational complexity inherent to cellular immunotherapy development and deployment.

A concise synthesis underscoring the critical alignment of technical innovation operational preparedness and strategic foresight required to realize cell therapy potential

In conclusion, cellular immunotherapy stands at an inflection point where scientific sophistication and operational readiness must align to fulfill therapeutic promise. Technological diversification is expanding clinical possibilities, yet it concurrently raises demands for manufacturing precision, supply chain robustness, and strategic partnership models that can support scale and consistent patient outcomes. Policy and trade dynamics introduce additional constraints that necessitate proactive sourcing strategies and scenario-based planning.

To navigate this environment, stakeholders should emphasize integrated planning that links clinical development to manufacturing capabilities and market access strategies. Investment in modular production capacity, supplier diversification, and evidence-generation frameworks will be essential to de-risk development programs and to facilitate adoption across heterogeneous regional markets. Ultimately, organizations that synchronize scientific innovation with operational excellence and strategic foresight will be best positioned to deliver meaningful clinical impact while building sustainable commercial trajectories for cellular immunotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cellular Immunotherapy Market, by Type

  • 8.1. CAR T-Cell Therapy
  • 8.2. Dendritic Cell Therapy
  • 8.3. NK Cell Therapy
  • 8.4. T-Cell Receptor Therapy
  • 8.5. Tumor-Infiltrating Lymphocytes Therapy

9. Cellular Immunotherapy Market, by Technology Type

  • 9.1. Cytokines & Immunomodulators
  • 9.2. Monoclonal Antibodies

10. Cellular Immunotherapy Market, by Indication

  • 10.1. B-Cell Malignancies
  • 10.2. Liver Cancer
  • 10.3. Prostate Cancer
  • 10.4. Renal Cell Carcinoma

11. Cellular Immunotherapy Market, by Institution Category

  • 11.1. Academic Institutes
  • 11.2. Biotech & Pharmaceutical Companies
  • 11.3. Contract Organizations
  • 11.4. Hospitals
  • 11.5. Research Institutes

12. Cellular Immunotherapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cellular Immunotherapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cellular Immunotherapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cellular Immunotherapy Market

16. China Cellular Immunotherapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adaptimmune Therapeutics PLC
  • 17.6. Adicet Bio, Inc.
  • 17.7. Apac Biotech Private Limited
  • 17.8. AstraZeneca PLC
  • 17.9. Atara Biotherapeutics, Inc.
  • 17.10. Bellicum Phamaceuticals, Inc.
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. Celyad Oncology SA
  • 17.14. Corning Incorporated
  • 17.15. Dendreon Pharmaceuticals LLC
  • 17.16. Eli Lilly and Company
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. Gilead Sciences, Inc.
  • 17.19. GlaxoSmithKline PLC
  • 17.20. Glycostem Therapeutics B.V.
  • 17.21. Immatics N.V.
  • 17.22. Inovio Pharmaceuticals, Inc.
  • 17.23. Iovance Biotherapeutics, Inc.
  • 17.24. Johnson & Johnson Services, Inc.
  • 17.25. JW Therapeutics (Shanghai) Co., Ltd.
  • 17.26. Lonza Group Ltd.
  • 17.27. Merck KGaA
  • 17.28. Novartis AG
  • 17.29. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY T-CELL RECEPTOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY BIOTECH & PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CONTRACT ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 101. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 116. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)